TMS Carlat Reports | Carlat Publishing

Research Update

From The Carlat Psychiatry Report, Psychotic Depression

Topics: Depression | rTMS | TMS | Transcranial Magnetic Stimulation | Treatment-Resistant Depression

REVIEW OF: Miuli A et al, World J Psychiatry 2021;11(8):477–490 STUDY TYPE: Literature review and meta-analysis Some treatments for depression, particularly antidepressants, present risk of manic reactions, but whether this risk exists with transcranial magnetic stimulation (TMS) is less clear. A group in Italy searched the world’s literatu

Expert Q&A

An Update on Neuromodulation Techniques for Older Adults

From The Carlat Geriatric Psychiatry Report, Anxiety

CGPR: One of the more interesting neuromodulation interventions is magnetic seizure therapy (MST). How does it work? Dr. Lisanby: MST is an investigational form of treatment for depression. Similar to electroconvulsive therapy (ECT), MST induces seizures with the intention of therapeutic benefit, but the big difference between MST and ECT is how the se

Expert Q&A

Electroconvulsive Therapy: A Primer

From The Carlat Hospital Psychiatry Report, Catatonia

CHPR: Welcome, Dr. Seiner. Can you tell us what led to your interest in electroconvulsive therapy (ECT) and neurotherapeutics? Dr. Seiner: I went to the University of Michigan and got a degree in chemical engineering, but I decided I didn’t want to fractionate oil for a living, so I went to medical school thinking I would be an internist. While in me

Research Update

The Role of rTMS in Poststroke Depression

From The Carlat Hospital Psychiatry Report, Testifying

REVIEW OF: Hordacre B et al, J Neurol 2021;268(4):1474–1484 STUDY TYPE: Randomized controlled trial Poststroke depression is common, disabling, and often treatment refractory. We know repetitive transcranial magnetic stimulation (rTMS) is effective for treatment-resistant depression. Might it offer a safe and effective treatment for poststroke d

Article

Transcranial Magnetic Stimulation (TMS) for Depression in Children and Adolescents

From The Carlat Child Psychiatry Report, Depression in Children and Adolescents

Editor’s note: This article is about the “usual” TMS that we have been hearing about for many years. We are covering trigeminal nerve stimulation (eTNS) separately in this issue in a News of Note as it is far newer with far less clarity about its utility. The search for safer treatment With concerns about both safety and efficacy surrounding a

Expert Q&A

Getting Uncomfortable with Esketamine

From The Carlat Psychiatry Report, Esketamine

Esketamine (Spravato) was approved for treatment-resistant depression in 2019. In this interview, Dr. Williams (who has no relationship with Janssen Pharmaceuticals, Inc) addresses some lingering doubts that have been raised about the medicine. TCPR: Where does esketamine fit in the list of interventional therapies for depression, like repetitive tra

Research Update

TMS: Deeper is not Better

From The Carlat Psychiatry Report, Esketamine

REVIEW OF: Filipcic I et al, J Psychiatr Res 2019;114:113–119 TYPE OF STUDY: Randomized single-blind controlled trial Seven transcranial magnetic stimulation (TMS) devices are FDA approved for depression, but only one—the Brainsway—is distinctly different from the others. Brainsway uses a patented H1 coil that penetrates deeper into the cortex t